Method for increasing the susceptibility of peptide deformylase inhibitors by using efflux pump inhibitors

Details for Australian Patent Application No. 2005259488 (hide)

Owner Novartis AG

Inventors Ryder, Neil Stewart; Dean, Charles Richard

Agent Davies Collison Cave

Pub. Number AU-B-2005259488

PCT Pub. Number WO2006/002896

Priority 60/584,023 30.06.04 US

Filing date 29 June 2005

Wipo publication date 12 January 2006

Acceptance publication date 1 October 2009

International Classifications

A61K 31/4439 (2006.01)

A61K 31/00 (2006.01)

A61K 31/167 (2006.01) - having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol

A61P 31/04 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Event Publications

11 January 2007 PCT application entered the National Phase

  PCT publication WO2006/002896 Priority application(s): WO2006/002896

1 October 2009 Application Accepted

  Published as AU-B-2005259488

28 January 2010 Standard Patent Sealed

27 January 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005259497-Disk brake for vehicles with a clamping device having a needle bearing

2005259487-Conjugates of antibody and duoarmycin derivatives as antitumor agents